Clinical Trial Update: Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating CEP-1347 for Parkinson's disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• CEP-1347 (CEP-1347)

Snippet

Sponsor: Cephalon | Conditions: Parkinson Disease | Phase 2, Phase 3 | Status: TERMINATED